The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells

Leukemia Research

Volumn 24, Issue 6, 2000, Pages 527-534

  Kang, Chi Dug ^a   Yoo, Seok Dong ^a   Hwang, Byung Wook ^a   Kim, Kwang Woon ^a   Kim, Dong Wan ^b   Kim, Cheol Min ^a   Kim, Sun Hee ^a   Chung, Byung Seon ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Department of Microbiology   (South Korea)

Author keywords

Apoptosis; Chronic myelogenous leukemia; ERK MAPK; JNK SAPK; K562 cells; PD98059

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; DNA FRAGMENT; HERBIMYCIN A; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN TYROSINE KINASE; SORBITOL; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL;

APOPTOSIS; BENZOQUINONES; DNA FRAGMENTATION; ENZYME ACTIVATION; ENZYME INHIBITORS; FLAVONOIDS; HL-60 CELLS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; K562 CELLS; LACTAMS, MACROCYCLIC; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; QUINONES; TUMOR CELLS, CULTURED;

EID: 0034001970     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00010-2     Document Type: Article

References (47)

1. Witte O.N. Role of the BCR-ABL oncogene in human leukemia: 15th Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 53:1993;485-489.
2. Kantarjian H.M., Deisseroth A., Kurzrock R., Estrov Z., Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 82:1993;691-703.
3. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 45:1975;321-334.
4. Campbell M.L., Lu D., Guo J.Q., Arlinghaus R.B. Inhibition of phosphorylation of p160 BCR within p210 BCR-ABL complexes during early stages of phorbol ester-induced differentiation of K562 cells. Cell. Growth Differ. 4:1993;581-588.
5. Kaufmann S.H., Desnoyers S., Ottaviano Y., Davidson N.E., Poirier G.G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 53:1993;3976-3985.
6. Chang M.P., Bramhall J., Graves S., Bonavida B., Wisnieski B.J. Internucleosomal DNA cleavage precedes diphtheria toxin-induced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition. J. Biol. Chem. 264:1989;15261-15267.
7. McGahon A., Bissonnette R., Schmitt M., Cotter K.M., Green D.R., Cotter T.G. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death [published erratum appears in Blood Jun 15;83(12):3835]. Blood. 83:1994;1179-1187.
8. McGahon A.J., Nishioka W.K., Martin S.J., Mahboubi A., Cotter T.G., Green D.R. Regulation of the Fas apoptotic cell death pathway by Abl. J. Biol. Chem. 270:1995;22625-22631.
9. Gangemi R.M., Tiso M., Marchetti C., Severi A.B., Fabbi M. Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother. Pharmacol. 36:1995;385-392.
10. Dubrez L., Goldwasser F., Genne P., Pommier Y., Solary E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia. 9:1995;1013-1024.
11. Ray S., Bullock G., Nunez G., Tang C., Ibrado A.M., Huang Y., Bhalla K. Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis. Cell. Growth Differ. 7:1996;1617-1623.
12. Dan S., Naito M., Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148. Cell. Death Differ. 5:1998;710-715.
13. le Coutre P., Mologni L., Cleris L., Marchesi E., Buchdunger E., Giardini R., Formelli F., Gambacorti-Passerini C. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor [see comments]. J. Natl. Cancer Inst. 91:1999;163-168.
14. Bedi A., Zehnbauer B.A., Barber J.P., Sharkis S.J., Jones R.J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 83:1994;2038-2044.
15. Rowley P.T., Keng P.C., Kosciolek B.A. The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells. Leuk. Res. 20:1996;473-480.
16. Bedi A., Barber J.P., Bedi G.C., el Deiry W.S., Sidransky D., Vala M.S., Akhtar A.J., Hilton J., Jones R.J. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 86:1995;1148-1158.
17. Martins L.M., Mesner P.W., Kottke T.J., Basi G.S., Sinha S., Tung J.S., Svingen P.A., Madden B.J., Takahashi A., McCormick D.J., Earnshaw W.C., Kaufmann S.H. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood. 90:1997;4283-4296.
18. Amarante-Mendes G.P., Naekyung K.C., Liu L., Huang Y., Perkins C.L., Green D.R., Bhalla K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3. Blood. 91:1998;1700-1705.
19. Dubrez L., Eymin B., Sordet O., Droin N., Turhan A.G., Solary E. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood. 91:1998;2415-2422.
20. Seger R., Krebs E.G. The MAPK signaling cascade. FASEB. J. 9:1995;726-735.
21. Johnson G.L., Vaillancourt R.R. Sequential protein kinase reactions controlling cell growth and differentiation. Curr. Opin. Cell. Biol. 6:1994;230-238.
22. Kyriakis J.M., Avruch J. Sounding the alarm: protein kinase cascades activated by stress and inflammation. J. Biol. Chem. 271:1996;24313-24316.
23. Freshney N.W., Rawlinson L., Guesdon F., Jones E., Cowley S., Hsuan J., Saklatvala J. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell. 78:1994;1039-1049.
24. Raingeaud J., Gupta S., Rogers J.S., Dickens M., Han J., Ulevitch R.J., Davis R.J. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 270:1995;7420-7426.
25. Rouse J., Cohen P., Trigon S., Morange M., Alonso Llamazares A., Zamanillo D., Hunt T., Nebreda A.R. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell. 78:1994;1027-1037.
26. Butterfield L., Storey B., Maas L., Heasley L.E. c-Jun NH2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation. J. Biol. Chem. 272:1997;10110-10116.
27. Chen Y.R., Wang X., Templeton D., Davis R.J., Tan T.H. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J. Biol. Chem. 271:1996;31929-31936.
28. Verheij M., Bose R., Lin X.H., Yao B., Jarvis W.D., Grant S., Birrer M.J., Szabo E., Zon L.I., Kyriakis J.M., Haimovitz F.A., Fuks Z., Kolesnick R.N. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature. 380:1996;75-79.
29. Seimiya H., Mashima T., Toho M., Tsuruo T. c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J. Biol. Chem. 272:1997;4631-4636.
30. Juo P., Kuo C.J., Reynolds S.E., Konz R.F., Raingeaud J., Davis R.J., Biemann H.P., Blenis J. Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases. Mol. Cell. Biol. 17:1997;24-35.
31. Graves J.D., Draves K.E., Craxton A., Saklatvala J., Krebs E.G., Clark E.A. Involvement of stress-activated protein kinase and p38 mitogen-activated protein kinase in mIgM-induced apoptosis of human B lymphocytes. Proc. Natl. Acad. Sci. USA. 93:1996;13814-13818.
32. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 270:1995;1326-1331.
33. Goillot E., Raingeaud J., Ranger A., Tepper R.I., Davis R.J., Harlow E., Sanchez I. Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc. Natl. Acad. Sci. USA. 94:1997;3302-3307.
34. Eilers A., Whitfield J., Babij C., Rubin L.L., Ham J. Role of the Jun kinase pathway in the regulation of c-Jun expression and apoptosis in sympathetic neurons. J. Neurosci. 18:1998;1713-1724.
35. Luo Y., Umegaki H., Wang X., Abe R., Roth G.S. Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J. Biol. Chem. 273:1998;3756-3764.
36. Chen Y.R., Wang W., Kong A.N., Tan T.H. Molecular mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates. J. Biol. Chem. 273:1998;1769-1775.
37. Gardner A.M., Johnson G.L. Fibroblast growth factor-2 suppression of tumor necrosis factor alpha-mediated apoptosis requires Ras and the activation of mitogen-activated protein kinase. J. Biol. Chem. 271:1996;14560-14566.
38. Parrizas M., Saltiel A.R., LeRoith D. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J. Biol. Chem. 272:1997;154-161.
39. Reuther J.Y., Reuther G.W., Cortez D., Pendergast A.M., Baldwin A.S. Jr A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 12:1998;968-981.
40. Raitano A.B., Whang Y.E., Sawyers C.L. Signal transduction by wild-type and leukemogenic Abl proteins. Biochim. Biophys. Acta. 1333:1997;F201-216.
41. Cortez D., Reuther G., Pendergast A.M. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene. 15:1997;2333-2342.
42. Marante-Mendes GP, Jascur T, Nishioka WK, Mustelin T, Green DR. Bcr-Abl-mediated resistance to apoptosis is independent of PI 3-kinase activity. Cell Death Diff 1997;4:548-554.
43. Kabarowski J.H., Allen P.B., Wiedemann L.M. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J. 13:1994;5887-5895.
44. Raitano A.B., Halpern J.R., Hambuch T.M., Sawyers C.L. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc. Natl. Acad. Sci. USA. 92:1995;11746-11750.
45. Owen Lynch P.J., Wong A.K., Whetton A.D. v-Abl-mediated apoptotic suppression is associated with SHC phosphorylation without concomitant mitogen-activated protein kinase activation. J. Biol. Chem. 270:1995;5956-5962.
46. Sakai N., Ogiso Y., Fujita H., Watari H., Koike T., Kuzumaki N. Induction of apoptosis by a dominant negative H-RAS mutant (116Y) in K562 cells. Exp. Cell. Res. 215:1994;131-136.
47. Cortez D., Stoica G., Pierce J.H., Pendergast A.M. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene. 13:1996;2589-2594.